Peripheral T-lymphocyte subsets in patients treated with Rituximab-Chlorambucil combination therapy for indolent NHL

Ann Hematol. 2006 Nov;85(11):813-4. doi: 10.1007/s00277-006-0170-9. Epub 2006 Aug 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Chlorambucil / pharmacology*
  • Chlorambucil / therapeutic use
  • Humans
  • Killer Cells, Natural
  • Lymphocyte Count
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / immunology
  • Rituximab
  • T-Lymphocyte Subsets / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Chlorambucil
  • Rituximab